Edition:
United States

People: Alkermes Plc (ALKS.O)

ALKS.O on Nasdaq

57.50USD
9:30am EDT
Change (% chg)

$-0.03 (-0.05%)
Prev Close
$57.53
Open
$57.50
Day's High
$57.50
Day's Low
$57.50
Volume
13,227
Avg. Vol
824,707
52-wk High
$63.40
52-wk Low
$41.93

Cooke, Shane 

Mr. Shane Cooke is President of the Company. Mr. Cooke is employed by Alkermes Pharma Ireland Limited, an Irish subsidiary of the Company. From May 2005 to September 16, 2011, Mr. Cooke served as a Director of Elan Corporation, plc (“Elan”). From May 2007 to September 16, 2011, Mr. Cooke was Executive Vice President of Elan and Head of Elan Drug Technologies. Mr. Cooke served as the Chief Financial Officer of Elan from July 2001, when he joined Elan, until May 2011. Prior to joining Elan, Mr. Cooke was Chief Executive of Pembroke Capital Limited, an aviation leasing company, and prior to that, held a number of senior positions in finance in the banking and aviation industries. He is a chartered accountant. He is currently on the board of directors of Prothena Biosciences and Prothena Therapeutics, both subsidiaries of publicly traded Prothena Corporation plc, as well as Endo International plc, a publicly traded company.

Basic Compensation

Total Annual Compensation, USD 561,847
Restricted Stock Awards, USD 903,560
Long-Term Incentive Plans, USD --
All Other, USD 2,679,460
Fiscal Year Total, USD 4,144,870

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Richard Pops

9,647,420

Shane Cooke

4,144,870

James Frates

2,678,060

Kathryn Biberstein

3,430,420

Elliot Ehrich

3,452,210

Iain Brown

--
As Of  30 Dec 2016